E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
localized epidermolysis bullosa simplex |
|
E.1.1.1 | Medical condition in easily understood language |
epidermolysis bullosa simplex |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Skin and Connective Tissue Diseases [C17] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10014989 |
E.1.2 | Term | Epidermolysis bullosa |
E.1.2 | System Organ Class | 10010331 - Congenital, familial and genetic disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Evaluation by the independent centralized assessor, to M3 versus baseline, of the global clinical improvement at the level of the sole of the foot handled by botulinique toxin vs. Untreated sole of the foot at grown-up patients affected by EBSL. |
|
E.2.2 | Secondary objectives of the trial |
Evaluation by the independent centralized assessor, to M6 versus baseline, the global clinical improvement Evaluation to M3 then to M6, respectively versus baseline, of the global clinical improvement Evaluation to M3 then to M6, respectively versus baseline, the efficiency of the treatment(processing) by toxin botulinique on the reduction of the number of hurts Evaluation to M3 then to M6, respectively versus baseline, the efficiency of the treatment(processing) by toxin botulinique on the reduction of the use of bandages Evaluation to M3 then to M6, respectively versus baseline, the efficiency by toxin botulinique of the treatment(processing) on the reduction of the cutaneous surface |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Diagnosis of LEBS based on clinical symptoms and in some cases histological or molecular findings • Palmar skin lesions: blisters and/or : erosions, edematous and erythematous lesions, crusts. 3 lesions per foot, as a minimum • Similar clinical severity of skin lesions on both feet • Patient aged 18 or older • Patient with social security • Written consent of the patient • Patient able to understand the study’s questionnaires
|
|
E.4 | Principal exclusion criteria |
• Patients with only one leg and a different number of toes on each foot. • Known hypersensitivity to botulinic toxin or its excipients • Current treatment with aminosides • Myasthenia • Swallowing difficulties • Past medical history of dysphagia or pneumopathy of inhalation • Known allergy or contraindications to lidocaine, prilocaine, paracetamol or nitrous oxide • Pregnancy (positive pregnancy test (β-HCG) for women of childbearing age, performed within the 2 days prior to the study. Breastfeeding. • Mental or physical or judicial incapacity to fill the questionnaires • Guardianship patients • Skin infection on the soles at the time of the inclusion • Skin lesions located on the soles, not related to LEBS (ie. post traumatic wound, wart) • Patient suffering from dishydrosis • Botulinic toxin injections in the previous 6 months • Inclusion in another study in the previous 2 months
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Global clinical improvement on each foot assessed by a blinded centralized independent reviewer using photographs, at M3 vs.baseline: IGA score (Improvement Global Assessment) assessed for each foot. IGA score is a 5-point scale 0=no improvement or worsening / 1=minimal improvement / 2=moderate improvement / 3=significant improvement / 4=total disappearance. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Day 1 (Baseline), Month 3 |
|
E.5.2 | Secondary end point(s) |
Global clinical improvement on each foot assessed by a blinded centralized independent reviewer using photographs, at M6 vs. baseline: IGA score (Improvement Global Assessment) for each foot. IGA score is a 5-point scale : 0=no improvement or worsening / 1=minimal improvement / 2=moderate improvement / 3=significant improvement / 4=total disappearance. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
day 1 (Baseline), Month 6 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |